Neck

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024
Head, Neck, Chung, Calreticulin, Vaccine, Immunogenic cell death, Endoplasmic reticulum, ICD, HMGB1, Reactive oxygen species, ATP, Poster, Autophagy, Research, Mouse, Abstract

The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).

Key Points: 
  • The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).
  • According to Moffitt’s abstract, “…in vitro findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells.
  • Notably, PV-10 promotes a significant increase in [reactive oxygen species], leading to an elevation in late apoptotic cells.
  • At the molecular level, a remarkable activation of endoplasmic reticulum (ER) stress, pro-apoptotic protein, and autophagy markers were observed.

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024
Therapy, Head, Neoplasm, Neck, CLS, AML, Part, TME, Sale, Pembrolizumab, Multiple myeloma, Bristol Myers Squibb, Symantec Endpoint Protection, TPS, Hyponatremia, Cytokine, Hypertension, Tumor microenvironment, Patient, Immunoglobulin A, MD Anderson Cancer Center, Hyperlipidemia, Disease, Biology, HNSCC, Hypercholesterolemia, CPS, PD-L1, Cancer, Pharmaceutical industry

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Retrieved on: 
Monday, March 4, 2024
Head, Neck, Recurrence, Toxicity, Anemia, Completeness, Radiation, SPECT/CT, Chemoradiotherapy, EBRT, Macroglobulinemia, Lymphocytopenia, Thrombocytopenia, Patient, Neutropenia, Survival, Poster, Cytopenia, Cancer, Pharmaceutical industry

The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).

Key Points: 
  • The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).
  • The data were presented in a poster at the 2024 Multidisciplinary Head and Neck Cancers Symposium held February 29-March 2, 2024, in Phoenix, AZ.
  • Complete remission was achieved in 64% of patients, with an ORR of 73% (n=11).
  • Observed adverse events were consistent with the known toxicity profile of iopofosine I 131, with cytopenias being the most common with all patients recovering.

Joni and Friends celebrates 45 years of disability ministry

Retrieved on: 
Monday, February 26, 2024
Neck, Diving, Tetraplegia, Hope, Hardship, Disability, Chronic pain, House, Practice, Joni

This year marks the 45th anniversary since the founding of the international disability ministry Joni and Friends.

Key Points: 
  • This year marks the 45th anniversary since the founding of the international disability ministry Joni and Friends.
  • For the past four-and-a-half decades, Joni and Friends has provided practical help and Gospel hope to individuals living with disability around the world.
  • Joni said she is astonished at what God has done through 45 years of ministry at Joni and Friends.
  • “God has done—and continues to do—astonishing things through Joni and Friends and 45 years of ministry is an astounding milestone!

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
Wednesday, February 21, 2024
Head, Breast cancer, Neck, Cancer, Woman, Survivor, Diet, Reproductive medicine, Assistant, Melanoma, Blood, Uterus, Biostatistics, Skin, Immunodeficiency, Database, Communication, Risk, FACP, Breast, University, Stomach, Vaccination, MD Anderson Cancer Center, Member of Congress, Genetic, Dicarboxylic acid, Drinking, Ovarian cancer, Genetics, Squamous-cell carcinoma, Death, Associate, Genetic testing, Black, Huntsman Cancer Institute, SCCS, Disease, HPV, Knowledge, Health literacy, Mortality, New York University, Research, University of North Carolina, Partnership, Birth control

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Retrieved on: 
Tuesday, February 20, 2024
PALO, Prevalence, Neck pain, Lidocaine, Physical medicine and rehabilitation, Neurology, Anesthesiology, American Medical Association, JAMA, Outline of health sciences, Disability, Chronic pain, Behavioural sciences, COVID, Patient, Journal, Neck, Psychiatry, Clutch (eggs), Rehabilitation, Pharmaceutical industry

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Key Points: 
  • PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
  • The primary outcome measure was mean reduction in average neck pain coupled with the Patient Global Impression of Change.
  • Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the 4th leading cause of disability.
  • According to a 2020 JAMA publication (Journal of the American Medical Association), the U.S. low back and neck pain market is estimated at $134.5B.4

UNITE HERE Local 11 Boycott of Hotel Figueroa and Restaurant Operator, The Botanical Group, Declared Following Firings, Shootings, and Unsettled Labor Dispute; Letter Signed by Hundreds Delivered

Retrieved on: 
Saturday, March 9, 2024
Public Policy, Government, Retail, Restaurant, Bar, Labor, Lodging, Travel, Weeping Angel, Strike, Neck, Violence, Sleep, Airport, Food, Letter, Risk, University, Safety, Economic justice, UNITE, UNITE HERE, HERE, Failure, Tourism

The worker-called boycott marks a significant escalation in a months-long labor dispute that began last July.

Key Points: 
  • The worker-called boycott marks a significant escalation in a months-long labor dispute that began last July.
  • UNITE HERE Local 11 has requested that the Office of Los Angeles City Attorney Hydee Feldstein Soto investigate potential violations of Los Angeles’ Hotel Worker Retention Ordinance .
  • You cannot treat people like this,” said Ada Briceño, co-president UNITE HERE Local 11.
  • UNITE HERE Local 11 is a labor union representing more than 32,000 hospitality workers in Southern California and Arizona that work in hotels, restaurants, universities, convention centers and airports.

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Friday, March 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NSCLC, Head, Cancer, Incidence, Neck, EGFR, Investment, Colorectal cancer, PSMA, Renal cell carcinoma, Șaeș, FINANCIAL, Therapy, Liver disease, Patient, PSA, RECIST, IP, FUTURE, CRS, Infrared spectroscopy correlation table, Prostate cancer

“2023 was a critical year for Janux as we tested the potential power of our TRACTr platform in the clinic.

Key Points: 
  • “2023 was a critical year for Janux as we tested the potential power of our TRACTr platform in the clinic.
  • RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:
    Presented positive updated interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer in February 2024.
  • Janux plans to deploy these funds to expand development of clinical programs, advance additional preclinical programs and extend corporate runway.
  • FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS:
    Cash and cash equivalents and short-term investments: As of December 31, 2023, Janux reported cash and cash equivalents and short-term investments of $344.0 million compared to $327.0 million at December 31, 2022.

Apollo Hospital in New Delhi Initiates First Non-Invasive ZAP-X Brain Tumor Treatment in South Asia

Retrieved on: 
Thursday, March 7, 2024
Technology, Medical Devices, Surgery, Hospitals, Health Technology, Other Health, Radiology, Robotics, Health, Oncology, Head, TK, Hospital, Neck, Neoplasm, Apollo, Multimedia, Pineal gland, Nausea, Vomiting, Stanford University, Apollo Hospitals, ZAP, Patient, Headache, Brain, Male, SRS, Radiation therapy, Stereotactic surgery, Partnership, Medical imaging

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Apollo Hospital in New Delhi, India, completed its first patient treatment using the new ZAP-X® Gyroscopic Radiosurgery® platform.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Apollo Hospital in New Delhi, India, completed its first patient treatment using the new ZAP-X® Gyroscopic Radiosurgery® platform.
  • This pioneering approach aims to maximally safeguard healthy brain tissue and preserve patient cognitive function.
  • “Pineal tumors are extremely difficult to remove with open surgery as they are anatomically located within the center of the brain.
  • “ZAP is honored to support Apollo Hospitals in expanding global access to this potentially life-saving treatment.”

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Head, Neoplasm, Neck, DAR, Toxicity, Therapeutic index, Cancer, Spacecraft, AACR, Lung, ADC, Annual general meeting, Breast, Safety, Stomach, Human, Ovarian cancer, Immunoglobulin G, Adenocarcinoma, Abstract, Patient, Poster, DNA repair, Translocase, Cell death, Biology, Cancer research, Esophagus, DNA, 5T4, Pharmaceutical industry

Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

Key Points: 
  • Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
  • The results we will present at the AACR Annual Meeting will highlight the preclinical differentiation of our two lead candidates, TUB-030 and TUB-040.
  • The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR journal, Cancer Research.
  • The company will issue a press release detailing the full preclinical data following the presentation at AACR.